WO1995011027A1 - Use of peniclorin for the treatment of posttherapeutic neuralgia - Google Patents
Use of peniclorin for the treatment of posttherapeutic neuralgia Download PDFInfo
- Publication number
- WO1995011027A1 WO1995011027A1 PCT/GB1994/002262 GB9402262W WO9511027A1 WO 1995011027 A1 WO1995011027 A1 WO 1995011027A1 GB 9402262 W GB9402262 W GB 9402262W WO 9511027 A1 WO9511027 A1 WO 9511027A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- acyclovir
- patients
- composition according
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- This invention relates to treatment of post-herpetic neuralgia, and to the use of compounds in the preparation of a medicament for use in the treatment of such conditions.
- EP-A-308065 discloses certain amino acid esters of the purine nucleoside, acyclovir including the compound, 2-[2-amino- l,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl L-valinate, valaciclovir, as having improved oral bioavailabilty as compared with the alanine and glycine esters of acyclovir, disclosed in EP-A-99493. The properties of valaciclovir are reviewed in 'Drugs of the Future, 18, 619-628).
- PPN Post-herpetic neuralgia
- acyclovir given 800 mg five times daily for seven to ten days has been the only oral antiviral agent approved for treatment of acute herpes zoster. Its effectiveness in lessening the acute signs and symptoms of herpes zoster has been established, but "the effects of acyclovir on postherpetic neuralgia are less clear cut," (Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks, J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. New Engl J Med.
- Postherpetic neuralgia is a common severe complication of herpes zoster.
- acyclovir herpes zoster trial McKendrick et al, Br Med J. 1989;298:431
- no difference was shown between acyclovir and placebo in either the incidence or the duration of postherpetic neuralgia, despite enrolling only those patients most at risk of developing postherpetic neuralgia (eg, elderly).
- two smaller trials uff et al. Am J Med. 1988;85 (Suppl 2A):84-9; Morton and Thompson, NZ Med J.
- the present invention provides a method of treatment of PHN in humans, which method comprises the administration to the human in need of such treatment, an effective amount of acyclovir or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.
- a particular compound of interest is valaciclovir, the well-absorbed oral form of acyclovir (ACN).
- the compound in particular, acyclovir or valaciclovir, may be administered by the oral route to humans and may be compounded in the form of syrup, tablets or capsule.
- any pharmaceutical carrier suitable for formulating such solid compositions may be used, for example magnesium stearate, starch, lactose, glucose, rice, flour and chalk.
- the compound may also be in the form of an ingestible capsule, for example of gelatin, to contain the compound, or in the form of a syrup, a solution or a suspension.
- Suitable liquid pharmaceutical carriers include ethyl alcohol, glycerine, saline and water to which flavouring or colouring agents may be added to form syrups.
- Sustained release formulations for example tablets containing an enteric coating, are also envisaged.
- fluid unit dose forms are prepared containing the compound and a sterile vehicle.
- the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
- Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
- compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
- An amount effective to treat the virus infection depends on the nature and severity of the infection and the weight of the mammal.
- a suitable dosage unit might contain from 50mg to lg of active ingredient, for example 800 mg in the case of acyclovir and 1000 mg in the case of valaciclovir. Such doses may be administered up to 5 times a day, 5 times a day in the case of acyclovir and 2 or 3 times per day in the case of valaciclovir.
- the effective dose of compound is based on administration to an adult of 70kg body weight.
- the treatment is preferably carried out as soon as possible after symptoms appear usually within 72 hours, preferably within 48 hours of rash onset and within 36 or 24 hours of rash onset if at all possible.
- the treatment period is usually 7 days although it may be less or more than this, for example 5, 6, 10. 14, 21 days or for an indefinite period.
- the treatment is particularly effective in the case of patients of greater than 50 years of age, and efficacy would be expected to be demonstrated further in patients greater than 60 years of age, especially patients of greater than 70 years of age.
- the present invention also provides the use of acyclovir or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing, in the preparation of a medicament for use in the treatment of PHN. Such treatment may be carried out in the manner as hereinbefore described.
- the present invention further provides a pharmaceutical composition for use in the treatment of PHN, which comprises an effective amount of acyclovir or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition for use in the treatment of PHN which comprises an effective amount of acyclovir or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing, and a pharmaceutically acceptable carrier.
- Such compositions may be prepared in the manner as hereinafter described. The following clinical data illustrate the invention.
- Clinical Data Patients >18 years of age with clinically diagnosed uncomplicated herpes zoster infection based on clinical judgment who gave written informed consent were eligible for study entry. Exclusion criteria included patients with zoster rash that had been present for >72 hours; complications of herpes zoster (eg, ocular or visceral involvement, disseminated zoster); presence of crusts at enrollment; patients with other serious underlying disease (eg, immunocompromised and/or HIN-infected individuals); or pregnant or lactating females.
- diseases of herpes zoster eg, ocular or visceral involvement, disseminated zoster
- presence of crusts at enrollment patients with other serious underlying disease (eg, immunocompromised and/or HIN-infected individuals); or pregnant or lactating females.
- Patients were prohibited from receiving any concomitant antiviral or immunomodifying therapy and any topical medication which would be applied to zoster lesions during the course of the study. Patients were instructed to return to the clinic for lesion and pain evaluations each of the seven therapy days and every day for the next seven days following therapy. Patients with lesions that were fully crusted by day 7 were examined every other day of the week following therapy. After day 14, weekly visits were required of all patients until all lesions had lost their crusts. Patients were assessed for the presence of postherpetic neuralgia at monthly intervals following healing for an additional five months.
- the number of papules, vesicles, ulcers, and crusts within the primary dermatome was recorded as none, mild ( ⁇ 25 lesions), moderate (25-50 lesions), or severe (>50 lesions).
- a specimen for viral culture was taken at baseline and daily thereafter while vesicles were present. Patients were asked to rate the intensity of their pain on a scale of none, mild, moderate, or severe.
- Time to event Timepoints at which at least 25% (Ql), 50% (Median), or 75% (Q3) of the patients no longer had pain
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7511498A JPH09503779A (en) | 1993-10-16 | 1994-10-14 | Use of pencicloline for the treatment of neuralgia after herpes |
AU78603/94A AU7860394A (en) | 1993-10-16 | 1994-10-14 | Use of peniclorin for the treatment of posttherapeutic neuralgia |
EP94929608A EP0723448A1 (en) | 1993-10-16 | 1994-10-14 | Use of peniclorin for the treatment of posttherapeutic neuralgia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939321394A GB9321394D0 (en) | 1993-10-16 | 1993-10-16 | Pharmaceuticals |
GB9321394.0 | 1993-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995011027A1 true WO1995011027A1 (en) | 1995-04-27 |
Family
ID=10743678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1994/002262 WO1995011027A1 (en) | 1993-10-16 | 1994-10-14 | Use of peniclorin for the treatment of posttherapeutic neuralgia |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0723448A1 (en) |
JP (1) | JPH09503779A (en) |
AU (1) | AU7860394A (en) |
BE (1) | BE1007586A3 (en) |
CA (1) | CA2174240A1 (en) |
FR (1) | FR2711061B1 (en) |
GB (2) | GB9321394D0 (en) |
WO (1) | WO1995011027A1 (en) |
ZA (1) | ZA948065B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID27395A (en) * | 1998-07-09 | 2001-04-05 | Warner Lambert Co | COMPOSITION OF DRUGS THAT CONTAIN ANALOGUE ANALOGUE AND ANTI VIRUS INGREDIENTS TO TREAT NERVOUS DISEASE |
-
1993
- 1993-10-16 GB GB939321394A patent/GB9321394D0/en active Pending
-
1994
- 1994-10-14 FR FR9412300A patent/FR2711061B1/en not_active Expired - Fee Related
- 1994-10-14 EP EP94929608A patent/EP0723448A1/en not_active Withdrawn
- 1994-10-14 JP JP7511498A patent/JPH09503779A/en active Pending
- 1994-10-14 GB GB9420754A patent/GB2282759A/en not_active Withdrawn
- 1994-10-14 WO PCT/GB1994/002262 patent/WO1995011027A1/en not_active Application Discontinuation
- 1994-10-14 BE BE9400928A patent/BE1007586A3/en not_active IP Right Cessation
- 1994-10-14 AU AU78603/94A patent/AU7860394A/en not_active Abandoned
- 1994-10-14 CA CA002174240A patent/CA2174240A1/en not_active Abandoned
- 1994-10-14 ZA ZA948065A patent/ZA948065B/en unknown
Non-Patent Citations (5)
Title |
---|
D.R.C. ROBERTSON ET AL: "Treatment of postherpetic neuralgia in the elderly.", BR. MED. BULL., vol. 46, no. 1, 1990, pages 1113 - 123 * |
J.E.F REYNOLDS: "martindale", 1982, THE PHARMACEUTICAL PRESS, LONDON. * |
K.E. SCHMADER ET AL.: "Are current therapies useful for the prevention of postherpetic neuralgia.", J. GEN. INTERN. MED., vol. 4, no. 2, 1989, pages 83 - 89 * |
M.J. WOOD ET AL.: "Herpes zoster and pain.", SCAND. J. INFECT. DIS., vol. 23, no. 80, 1991, pages 53 - 61 * |
P.KLENERMAN ET AL.: "Acyclovir and postherpetic neuralgia.", BIOMED. PHARMACOTHER., vol. 4, no. 2, 1990, pages 455 - 459 * |
Also Published As
Publication number | Publication date |
---|---|
ZA948065B (en) | 1996-04-10 |
EP0723448A1 (en) | 1996-07-31 |
GB2282759A (en) | 1995-04-19 |
JPH09503779A (en) | 1997-04-15 |
AU7860394A (en) | 1995-05-08 |
GB9321394D0 (en) | 1993-12-08 |
BE1007586A3 (en) | 1995-08-16 |
FR2711061A1 (en) | 1995-04-21 |
GB9420754D0 (en) | 1994-11-30 |
FR2711061B1 (en) | 1995-12-01 |
CA2174240A1 (en) | 1995-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0320222A (en) | Remedy for ischemic disease in brain | |
WO1999012545A2 (en) | Medicaments containing acyclovir | |
EP0689437B1 (en) | Use of granisetron for the treatment of post-operative nausea and vomiting | |
US20090062315A1 (en) | Pharmaceutical Acceptable Composition Containing Non-Steroidal Anti-Inflammatory Drug and Local Anesthetics | |
AU7860394A (en) | Use of peniclorin for the treatment of posttherapeutic neuralgia | |
JP2000507211A (en) | Nucleoside analogs in combination therapy for herpes simplex infection | |
AU699627B2 (en) | Use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpes virus infections | |
AP616A (en) | Treatment of post-herpetic neuralgia with antiviral guanine derivatives. | |
EP1865961B1 (en) | Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment | |
JPH09506883A (en) | Drug | |
AU2010201836C1 (en) | Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment | |
US20120329815A1 (en) | Famciclovir for the Treatment of Recurrent Herpes Labialis using a One-Day Treatment | |
MXPA97004336A (en) | Use of antiviral agents for the treatment and prophylaxis of latent infections of herpesvi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 274537 Country of ref document: NZ Ref document number: 1994929608 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2174240 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1994929608 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994929608 Country of ref document: EP |